Related references
Note: Only part of the references are listed.Treatment of Advanced Melanoma in 2020 and Beyond
Russell W. Jenkins et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
Lokeswari P. Tangella et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2021)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
NAD+ metabolism, stemness, the immune response, and cancer
Lola E. Navas et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Christine M. Heske
FRONTIERS IN ONCOLOGY (2020)
Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer
Van K. Morris et al.
CLINICAL CANCER RESEARCH (2020)
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy
Ubaldina Galli et al.
FRONTIERS IN PHARMACOLOGY (2020)
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation
Valentina Audrito et al.
FRONTIERS IN ONCOLOGY (2020)
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
Valentina Audrito et al.
CANCERS (2020)
NAD+metabolism: pathophysiologic mechanisms and therapeutic potential
Na Xie et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Clinical Development of BRAF plus MEK Inhibitor Combinations
Vivek Subbiah et al.
TRENDS IN CANCER (2020)
Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
Amit J. Sabnis et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling
Sudhir Chowdhry et al.
NATURE (2019)
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
Fabiana Crispo et al.
CANCERS (2019)
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Imanol Arozarena et al.
NATURE REVIEWS CANCER (2019)
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma
Valentina Audrito et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Andrew M. Waters et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma
Valentina Audrito et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype
Mickael Ohanna et al.
GENES & DEVELOPMENT (2018)
The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges
Maria Dalamaga et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Matthew Dankner et al.
ONCOGENE (2018)
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
Valentina Audrito et al.
Oncotarget (2018)
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
Paola Falletta et al.
GENES & DEVELOPMENT (2017)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
Physiological and pathophysiological roles of NAMPT and NAD metabolism
Antje Garten et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecular drivers of cellular metabolic reprogramming in melanoma
Cecilie Abildgaard et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome
Piotr Rutkowski et al.
ONCOLOGY LETTERS (2014)
Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis
Zsuzsa Rakosy et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52
Jennifer D. Lewis et al.
MOLECULAR CANCER RESEARCH (2007)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death
L Ricci-Vitiani et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
